TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis
USA - NASDAQ:TGTX - US88322Q1085 - Common Stock
36.66 USD
+0.1 (+0.27%)
36.66 USD
0 (0%)
Taking everything into account, TGTX scores 5 out of 10 in our fundamental rating. TGTX was compared to 536 industry peers in the Biotechnology industry. Both the profitability and the financial health of TGTX get a neutral evaluation. Nothing too spectacular is happening here. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
TGTX had positive earnings in the past year.
TGTX had a negative operating cash flow in the past year.
In multiple years TGTX reported negative net income over the last 5 years.
In the past 5 years TGTX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of TGTX (8.60%) is better than 92.91% of its industry peers.
Looking at the Return On Equity, with a value of 21.87%, TGTX belongs to the top of the industry, outperforming 96.46% of the companies in the same industry.
With an excellent Return On Invested Capital value of 12.78%, TGTX belongs to the best of the industry, outperforming 94.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.6% | ||
| ROE | 21.87% | ||
| ROIC | 12.78% |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 13.31%, TGTX belongs to the top of the industry, outperforming 92.91% of the companies in the same industry.
The Operating Margin of TGTX (18.91%) is better than 94.03% of its industry peers.
TGTX has a better Gross Margin (86.96%) than 89.37% of its industry peers.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.91% | ||
| PM (TTM) | 13.31% | ||
| GM | 86.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TGTX is creating some value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
Compared to 5 years ago, TGTX has more shares outstanding
Compared to 1 year ago, TGTX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.10 indicates that TGTX is not in any danger for bankruptcy at the moment.
TGTX has a better Altman-Z score (7.10) than 79.85% of its industry peers.
TGTX has a Debt/Equity ratio of 0.89. This is a neutral value indicating TGTX is somewhat dependend on debt financing.
TGTX has a Debt to Equity ratio of 0.89. This is in the lower half of the industry: TGTX underperforms 75.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.1 |
ROIC/WACC1.27
WACC10.08%
2.3 Liquidity
A Current Ratio of 3.86 indicates that TGTX has no problem at all paying its short term obligations.
With a Current ratio value of 3.86, TGTX perfoms like the industry average, outperforming 44.78% of the companies in the same industry.
A Quick Ratio of 2.96 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a worse Quick ratio (2.96) than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.86 | ||
| Quick Ratio | 2.96 |
3. Growth
3.1 Past
TGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.33%.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 30.96%.
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 364.59% on average per year.
EPS 1Y (TTM)-38.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)30.96%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.13%
3.2 Future
The Earnings Per Share is expected to grow by 100.25% on average over the next years. This is a very strong growth
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.77% yearly.
EPS Next Y465.86%
EPS Next 2Y272.39%
EPS Next 3Y157.37%
EPS Next 5Y100.25%
Revenue Next Year83.91%
Revenue Next 2Y63.29%
Revenue Next 3Y50.3%
Revenue Next 5Y38.77%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 99.08, the valuation of TGTX can be described as expensive.
Based on the Price/Earnings ratio, TGTX is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
TGTX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.86.
The Price/Forward Earnings ratio is 18.88, which indicates a rather expensive current valuation of TGTX.
93.28% of the companies in the same industry are more expensive than TGTX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of TGTX to the average of the S&P500 Index (23.29), we can say TGTX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 99.08 | ||
| Fwd PE | 18.88 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaper than 90.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 66.22 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TGTX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 157.37% in the coming years.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y272.39%
EPS Next 3Y157.37%
5. Dividend
5.1 Amount
TGTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
36.66
+0.1 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners64.52%
Inst Owner Change3.14%
Ins Owners9.73%
Ins Owner Change0.3%
Market Cap5.82B
Analysts78.67
Price Target42.84 (16.86%)
Short Float %17.17%
Short Ratio10.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.54%
Min EPS beat(2)-83.83%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-15.86%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)4
Avg EPS beat(8)69.34%
EPS beat(12)6
Avg EPS beat(12)43.68%
EPS beat(16)8
Avg EPS beat(16)35.05%
Revenue beat(2)1
Avg Revenue beat(2)-3.03%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)0.05%
Revenue beat(4)3
Avg Revenue beat(4)0.18%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)35.09%
Revenue beat(12)8
Avg Revenue beat(12)17.26%
Revenue beat(16)10
Avg Revenue beat(16)22.77%
PT rev (1m)0%
PT rev (3m)-1.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.16%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 99.08 | ||
| Fwd PE | 18.88 | ||
| P/S | 12.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 21.04 | ||
| P/tB | 21.04 | ||
| EV/EBITDA | 66.22 |
EPS(TTM)0.37
EY1.01%
EPS(NY)1.94
Fwd EY5.3%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS2.86
BVpS1.74
TBVpS1.74
PEG (NY)0.21
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.6% | ||
| ROE | 21.87% | ||
| ROCE | 16.18% | ||
| ROIC | 12.78% | ||
| ROICexc | 24.32% | ||
| ROICexgc | 24.32% | ||
| OM | 18.91% | ||
| PM (TTM) | 13.31% | ||
| GM | 86.96% | ||
| FCFM | N/A |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score3
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.85 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 3.33 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.86 | ||
| Quick Ratio | 2.96 | ||
| Altman-Z | 7.1 |
F-Score3
WACC10.08%
ROIC/WACC1.27
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y465.86%
EPS Next 2Y272.39%
EPS Next 3Y157.37%
EPS Next 5Y100.25%
Revenue 1Y (TTM)30.96%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.13%
Revenue Next Year83.91%
Revenue Next 2Y63.29%
Revenue Next 3Y50.3%
Revenue Next 5Y38.77%
EBIT growth 1Y-15.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year433.86%
EBIT Next 3Y127.45%
EBIT Next 5YN/A
FCF growth 1Y63.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.11%
OCF growth 3YN/A
OCF growth 5YN/A